Novo Nordisk shares pop 5% after Wegovy receives U.S. approval for liver disease
- Posted on August 18, 2025
- By CNBC
- 2 Views
Novo Nordisk shares pop 5% after Wegovy receives U.S. approval for liver disease
The firm was granted U.S. approval for the treatment of metabolic dysfunction-associated steatohepatitis in adults with moderate to advanced liver fibrosis.
